Human Head and Neck Cancer Stem Cell - Frozen Vial
Also Avaliable as:
T25 plated cells $550.00 shipped at room temperature. Cat# 36125-52-T25
T75 plated cells $750.00 shipped at room temperature. Cat# 36125-52-T75
120 Population doublings or up to 12 passages.
One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice.
This product would require pre-coated flasks with Human Head and Neck Cancer Stem Cell Extra-cellular Matrix Cat# E36125-52 and Human Head and Neck Cancer Stem Cell Media Cat# M36125-52
Cell Cultures from single donors, 1000 different cell cultures available, please indicate which lots you require from the 1000 donors, or any subcategories of the cancer type at the time of order. If you do not specify the subcategory, we will provide you the Human Head and Neck CSC, randomly from our inventory.
Source: Human Head and Neck Cancer tissue
Positive Markers: CD133, CD44, SSEA3/4, Oct4, Tumorigenicity (< 1000 cells), Alkaline Phosphatase, Aldehyde Dehydrogenase, Telomerase, Nestin
For non-academic use, please inquire for pricing.
Cells are only guaranteed with purchase of Celprogen Media and Celprogen Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.
Angela B.Y. Hui, Michelle Lenarduzzi, Tiffaney Krushel, et al. Comprehensive MicroRNA Profiling for Head and Neck Squamous Cell Carcinomas. Clin Cancer Res 2010;16:1129-1139.
1000 individual donors are fully characterized proprietary patient-derived xenografts (PDX) representing all major histotypes and capturing tumor diversity.
Subcutaneous, orthotopic and disseminated models. Extensive molecular and pharmacological characterization as well as information on patients' pretreatment to help you select the most appropriate model.
Integrated approach: use the same PDX models and/or the corresponding cell line in 2D/3D screening assays and follow-up in vivo studies, identify biomarkers predicting tumor sensitivity for your compound. PDX Model: PDX36125-52
Individually tailored study designs: proof of concept, dose level and schedule optimization, combinations, biomarker identification, etc.